262 related articles for article (PubMed ID: 25483241)
1. Early protection in sheep against intratypic heterologous challenge with serotype O foot-and-mouth disease virus using high-potency, emergency vaccine.
Horsington J; Zhang Z; Bittner H; Hole K; Singanallur NB; Alexandersen S; Vosloo W
Vaccine; 2015 Jan; 33(3):422-9. PubMed ID: 25483241
[TBL] [Abstract][Full Text] [Related]
2. Protective effects of high-potency FMDV O
Horsington J; Perez CB; Maradei E; Novo SG; Gonzales JL; Singanallur NB; Bonastre P; Vosloo W
Vaccine; 2017 Sep; 35(38):5179-5185. PubMed ID: 28789849
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of a high potency O1 Manisa monovalent vaccine against heterologous challenge with foot-and-mouth disease virus of O/SEA/Mya-98 lineage in sheep.
Singanallur NB; Pacheco JM; Arzt J; Stenfeldt C; Fosgate GT; Rodriguez L; Vosloo W
Antiviral Res; 2017 Sep; 145():114-122. PubMed ID: 28780422
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of a high potency O1 Manisa monovalent vaccine against heterologous challenge with a FMDV O Mya98 lineage virus in pigs 4 and 7 days post vaccination.
Wilna V; Hong NT; Geoffrey FT; Jacqueline MM; Jianning W; Van Phuc K; Ngon QV; Phuong le TT; Hung D; Hanh TX; Van Hung V; Anh le TQ; Tien MT; Quang le TV; Long NT; Nagendrakumar SB
Vaccine; 2015 Jun; 33(24):2778-85. PubMed ID: 25917677
[TBL] [Abstract][Full Text] [Related]
5. Adenovirus-vectored foot-and-mouth disease vaccine confers early and full protection against FMDV O1 Manisa in swine.
Fernandez-Sainz I; Medina GN; Ramirez-Medina E; Koster MJ; Grubman MJ; de Los Santos T
Virology; 2017 Feb; 502():123-132. PubMed ID: 28039799
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of a high quality O
Galdo Novo S; Malirat V; Maradei ED; Pedemonte AR; Espinoza AM; Smitsaart E; Lee KN; Park JH; Bergmann IE
Vaccine; 2018 Mar; 36(12):1570-1576. PubMed ID: 29472132
[TBL] [Abstract][Full Text] [Related]
7. Protection in sheep against heterologous challenge with serotype Asia-1 foot-and-mouth disease virus using high potency vaccine.
Horsington J; Nfon C; Gonzales JL; Singanallur N; Bittner H; Vosloo W
Vaccine; 2018 Oct; 36(41):6095-6102. PubMed ID: 30195485
[TBL] [Abstract][Full Text] [Related]
8. Clinical protection, sub-clinical infection and persistence following vaccination with extinction payloads of O1 Manisa Foot-and-Mouth Disease monovalent vaccine and challenge in goats and comparison with sheep.
Madhanmohan M; Nagendrakumar SB; Kumar R; Anilkumar J; Manikumar K; Yuvaraj S; Srinivasan VA
Res Vet Sci; 2012 Oct; 93(2):1050-9. PubMed ID: 22079173
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of a high potency O
Fishbourne E; Ludi AB; Wilsden G; Hamblin P; Statham B; Bin-Tarif A; Brocchi E; Grazioli S; Dekker A; Eblé P; King DP
Vaccine; 2017 May; 35(20):2761-2765. PubMed ID: 28396208
[TBL] [Abstract][Full Text] [Related]
10. Effect of emergency FMD vaccine antigen payload on protection, sub-clinical infection and persistence following direct contact challenge of cattle.
Cox SJ; Voyce C; Parida S; Reid SM; Hamblin PA; Hutchings G; Paton DJ; Barnett PV
Vaccine; 2006 Apr; 24(16):3184-90. PubMed ID: 16488060
[TBL] [Abstract][Full Text] [Related]
11. Cross-protective efficacy of the O1 Manisa + O 3039 bivalent vaccine and the O 3039 monovalent vaccine against heterologous challenge with FMDV O/Jincheon/SKR/2014 in pig.
Kim T; Hong JK; Oem JK; Lee KN; Lee HS; Kim YJ; Ryoo S; Ko YJ; Park JH; Choi J; Lee SH; Jo HJ; Lee MH; Kim B; Kim J
Vaccine; 2019 Mar; 37(12):1702-1709. PubMed ID: 30712811
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of cross-protection between O1 Manisa and O1 Campos in cattle vaccinated with foot-and-mouth disease virus vaccine incorporating different payloads of inactivated O1 Manisa antigen.
Nagendrakumar SB; Srinivasan VA; Madhanmohan M; Yuvaraj S; Parida S; Di Nardo A; Horsington J; Paton DJ
Vaccine; 2011 Feb; 29(10):1906-12. PubMed ID: 21236232
[TBL] [Abstract][Full Text] [Related]
13. A Malaysia 97 monovalent foot-and-mouth disease vaccine (>6PD50/dose) protects pigs against challenge with a variant FMDV A SEA-97 lineage virus, 4 and 7 days post vaccination.
Nagendrakumar SB; Hong NT; Geoffrey FT; Jacqueline MM; Andrew D; Michelle G; Van Phuc K; Ngon QV; Phuong le TT; Phuc NN; Hanh TX; Van Hung V; Quynhanh le T; Tan TM; Long NT; Wilna V
Vaccine; 2015 Aug; 33(36):4513-9. PubMed ID: 26192355
[TBL] [Abstract][Full Text] [Related]
14. The B-cell response to foot-and-mouth-disease virus in cattle following vaccination and live-virus challenge.
Grant CFJ; Carr BV; Singanallur NB; Morris J; Gubbins S; Hudelet P; Ilott M; Charreyre C; Vosloo W; Charleston B
J Gen Virol; 2016 Sep; 97(9):2201-2209. PubMed ID: 27260141
[TBL] [Abstract][Full Text] [Related]
15. Comparison of immune responses after intra-typic heterologous and homologous vaccination against foot-and-mouth disease virus infection in pigs.
Eblé PL; de Bruin MG; Bouma A; van Hemert-Kluitenberg F; Dekker A
Vaccine; 2006 Feb; 24(9):1274-81. PubMed ID: 16289709
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of cross-protection against three topotypes of serotype O foot-and-mouth disease virus in pigs vaccinated with multi-epitope protein vaccine incorporated with poly(I:C).
Cao Y; Lu Z; Li D; Fan P; Sun P; Bao H; Fu Y; Li P; Bai X; Chen Y; Xie B; Liu Z
Vet Microbiol; 2014 Jan; 168(2-4):294-301. PubMed ID: 24345411
[TBL] [Abstract][Full Text] [Related]
17. Cross-protective efficacy of engineering serotype A foot-and-mouth disease virus vaccine against the two pandemic strains in swine.
Zheng H; Lian K; Yang F; Jin Y; Zhu Z; Guo J; Cao W; Liu H; He J; Zhang K; Li D; Liu X
Vaccine; 2015 Oct; 33(43):5772-5778. PubMed ID: 26431990
[TBL] [Abstract][Full Text] [Related]
18. Protection against direct-contact challenge following emergency FMD vaccination of cattle and the effect on virus excretion from the oropharynx.
Cox SJ; Voyce C; Parida S; Reid SM; Hamblin PA; Paton DJ; Barnett PV
Vaccine; 2005 Jan; 23(9):1106-13. PubMed ID: 15629353
[TBL] [Abstract][Full Text] [Related]
19. Induction of mucosal immune responses and protection of cattle against direct-contact challenge by intranasal delivery with foot-and-mouth disease virus antigen mediated by nanoparticles.
Pan L; Zhang Z; Lv J; Zhou P; Hu W; Fang Y; Chen H; Liu X; Shao J; Zhao F; Ding Y; Lin T; Chang H; Zhang J; Zhang Y; Wang Y
Int J Nanomedicine; 2014; 9():5603-18. PubMed ID: 25506214
[TBL] [Abstract][Full Text] [Related]
20. Use of ENABL® adjuvant to increase the potency of an adenovirus-vectored foot-and-mouth disease virus serotype A subunit vaccine.
Barrera J; Schutta C; Pisano M; Grubman MJ; Brake DA; Miller T; Kamicker BJ; Olutunmbi F; Ettyreddy D; Brough DE; Butman BT; Neilan JG
Vaccine; 2018 Feb; 36(8):1078-1084. PubMed ID: 29358056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
